LEI:
549300Q7EXQQH6KF7Z84
14 January 2025
RTW Biotech Opportunities
Ltd
Additional Investment in Numab Therapeutics
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to note an
additional investment in the Series C
extension of Numab
Therapeutics ("Numab"), a Swiss clinical
stage biotech advancing a proprietary pipeline of multi-specific
antibodies in immunology and oncology.
Numab announced the completion of
its CHF 50 million
(~US$55m) Series C extension, in which the Company participated
alongside other investment vehicles managed by RTW
Investments, LP (the "Investment Manager"). The extension
brought total Series C funding to CHF 180 million (~US$196m). The
funds will be used to support the advancement of multiple
potentially first-in-class and best-in-class programs into clinical
development. The Company first invested in Numab's original Series
C round in May of 2021.
Roderick Wong, Managing Partner and CIO
at the Investment Manager said,
"We are delighted to continue supporting
Numab Therapeutics. Their innovative approach to developing
multi-specific antibodies is particularly promising, and we believe
that their groundbreaking research and development efforts hold
great potential for transforming autoimmune and cancer treatments.
Following J&J's announcement last summer to acquire Numab
subsidiary, Yellow Jersey Therapeutics, we are optimistic that our
continued partnership and this latest financing round will
contribute to other significant advancements in immunology and
oncology therapeutics."
The full text of the announcement can be
accessed at
https://www.numab.com.
For Further
Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
Cadarn Capital (PR & Communications/Distribution & IR
Partner)
|
+44
79 8418 4461
|
Lucy Clark (PR)
|
Lucy@cadarncapital.com
|
David Harris
(Distribution)
|
+44
73 6888 3211
david@cadarncapital.com
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield
|
+44
20 7260 1000
|
Nathan Brown
|
|
Euan Brown
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44 14 8170 3100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
|
|
About
Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
**********